|
Today's Headlines
FDA is warning the public that azithromycin (Zithromax or Zmax; Pfizer) can cause abnormal changes in the electrical activity of the heart that may lead to potentially fatal cardiac arrhythmias
» Full article
|
|
FDA's Vaccines and Related Biological Products Advisory Committee recently held a meeting to make recommendations for the composition of the 2013-2014 influenza vaccine. The panel determined the new trivalent vaccinewill retain a current strain but 2 other strains will be replaced. » Full article
|
|
The Centers for Disease Control and Prevention (CDC) reported that carbapenem-resistant enterobacteriaceae (CRE) has increased over the last decade and most cases of resistance are associated with healthcare exposures. To slow the dissemination of CRE infections, local and state health departments need to take the lead in prevention efforts, according to CDC's Morbidity and Mortality Weekly Report released on March 5. » Full article
|
|
The first interim results in HCV/HIV co-infected patients from Boehringer Ingelheim's ongoing hepatitis C (HCV) clinical trial program, HCVerso, have become available. These results, from the phase 3 trial STARTVerso 4, were presented recently at the 20th annual Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta. » Full article
|
ADVERTISEMENT
 Download Case Study
: Reduce Rx Costs and Improve Member Health
Denying high-priced Rx claims may contain costs in the short term, but this practice can lead to poor adherence and complications for patients.
Download this case study to learn how health plans can reduce drug spend with more affordable medication alternatives and provider and member education.
|
|
CONTINUING EDUCATION
Welcome to the seventh and last knowledge-based activity in our CPE series: Medication Therapy Management (MTM) in Patients with Diabetes, which has been designed for pharmacists who take care of patients with diabetes. You can earn up to 14 credits from September 2012-March 2013 with 7 monthly knowledge-based activities. The March activity covers drug-induced hyperglycemia and hypoglycemia, nonprescription medications, and complementary and alternative medicine for diabetes care.
To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login.
Welcome to Case Studies in Diabetes Care-Part 1. This is the first of three studies offering you an opportunity to apply diabetes management concepts from the knowledge-based diabetes series. Earn 1 hour of CPE credit by completing this application-based activity.
Log in: www.drugtopics.com/casestudies
To begin, click on Course Catalog ID: 2013-02-2.
Coming soon - All users will be required to provide their NABP e-Profile ID when logging into the Drug Topics' FREE CPE. This new process requires all pharmacists and pharmacy technicians to provide their NABP e-Profile ID prior to accessing the system. If you have not done so, you can obtain your NABP e-Profile ID now at www.MyCPEmonitor.net This profile will enable you to have one login for all the NABP programs and services you will need throughout your career.
|
|
EDITOR'S PICK
Canagliflozin, a sodium glucose co-transporter inhibitor, offers a novel approach to the treatment of type 2 diabetes mellitus, and is under investigation for the treatment of this condition. A new drug application (NDA) for canagliflozin was submitted to FDA on May 31, 2012 by ¬Janssen Pharmaceuticals. On January 10, 2013, the US Food and Drug advisory panel voted 10 to 5 in support of approving canagliflozin (Invokana) for the management of adult type 2 diabetes mellitus patients. » Full article
|
|
|
Like
Tweet
